* TXCELL *
2001 - Méditerranée
Sophia Antipolis
(near Nice)
www.txcell.com Discovery, Immunology
Key words: Cell Therapy, Inflammatory, Autoimmune diseases
Mission: to develop new therapies to cure inflammatory and autoimmune diseases, such as Crohn's disease, multiple sclerosis, psoriasis or rheumatoid arthritis, by bringing regulatory T cells to the body
Clients: Prescribers
info@txcell.com
Age: 11 year(s)
Identity| TYPE/MANAGEMENT/INVESTORS | FINANCES/STATUS |
|---|
| Spin-off |
Managing Dir.-CEO: Meyer (François) [born 1948, Ph.D. molecular biology, ex-Ciba-Geigy, Sandoz, Rhone Poulenc Rorer, Aventis]
Sc.Dir.-CSO: Foussat (Arnaud) [Ph.D., ex-Inserm]
Med.Dir.-CMO: Forte (Miguel) [M.D., Ph.D., ex-B.M.S., Nabi Pharmaceuticals, UCB]
Fin.Dir.-CFO: Sarlot (Christophe)
BusDev:
Financers (Hist.): Auriga Partners, AXA Private Equity, BioAm, CDC, SPEF Venture, Inserm-Transfert | Turnover (M€) : n.a.
Total funding (M€) : 21.0
Last funding (M€) : 10.5
Focus : Inflammation
Position : Clinical
Company confirm : none |
History | DATE | MILESTONE | TYPE | TIME |
|---|
| 2011 .06 | Clinical trial (phase IIb) for OvaSave in Crohn's Disease (beginning, extension of CATS1 phase I/II) | CLIN | [10 years] |
| 2011 .03 | Nomination : François Meyer, as CEO (replacing Frédéric Hammel, following a legal decision of backup procedure) | ORGN | [9 years] |
| 2010 .04 | Clinical trial (phase II) for OvaSave in Crohn's Disease (positive preliminary results) | CLIN | [9 years] |
| 2008 .03 | 2nd round-financing : 10.5 M€, by previous shareholders | RFINB | [6 years] |
| 2006 .00 | Nomination : Frédéric Hammel [born 1966], as CEO (H. Groux in supervisory board) | ORGN | [4 years] |
| 2004 .10 | 1st round-financing : 10.5 M€, by Auriga Partners, AXA Private Equity, BioAm, CDC and SPEF Venture | RFINA | [3 years] |
| 2004 .00 | Nomination : Philippe Ballero [ex-Yamanouchi, Proskelia], as CEO | ORGN | [2 years] |
| 2001 .04 | Company founded by Dr Hervé Groux [CSO, ex-Inserm, CNRS] and Dr Françoise Cottrez, within Nice Archet Hospital, as a spin-off from Inserm | ORGF | [0 year] | Actualisation / Updating: 28-Sep-2011 |
|
